Christopher Vinnard1, Shruthi Ravimohan2, Neo Tamuhla3, Vijay Ivaturi4, Jotam Pasipanodya5, Shashikant Srivastava5, Chawangwa Modongo3, Nicola M Zetola3, Drew Weissman2, Tawanda Gumbo5, Gregory P Bisson2. 1. Public Health Research Institute, New Jersey Medical School, Newark, New Jersey, USA. 2. University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. 3. Pennsylvania Botswana-UPenn Partnership, Gaborone, Botswana. 4. Center for Translational Medicine, University of Maryland, Baltimore, Maryland, USA. 5. Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA.
Abstract
AIMS: Immune activation, which is characteristic of both tuberculosis (TB) and human immunodeficiency virus (HIV) infection, is associated with impaired drug metabolism. We tested the hypothesis that elevated levels of systemic immune activation among adults with HIV/TB initiating antiretroviral therapy (ART) would be associated with impaired clearance of isoniazid. METHODS: We conducted a prospective observational study of isoniazid pharmacokinetics (PK) and systemic immune activation prior to and 1 month after ART initiation. Nonlinear mixed effects analysis was performed to measure the covariate effect of immune activation on isoniazid clearance in a model that also included N-acetyltransferase-2 (NAT-2) genotype and interoccasional variability on clearance (thereby analyzing the PK data before and after ART initiation in a single model). RESULTS: We enrolled 40 patients in the PK visit prior to ART, and 24 patients returned for the second visit a median of 33 days after initiating antiretroviral therapy. The isoniazid concentration data were best described by a two-compartment model with first-order elimination. After accounting for NAT-2 genotype, increasing levels of CD38 and HLA-DR expression on CD8+ T cells (CD38+ DR+ CD8+ ) were associated with decreasing isoniazid clearance. CONCLUSION: HIV/TB patients with high levels of immune activation demonstrated impaired isoniazid clearance. Future efforts should determine the role of this relationship in clinical hepatotoxicity events.
AIMS: Immune activation, which is characteristic of both tuberculosis (TB) and human immunodeficiency virus (HIV) infection, is associated with impaired drug metabolism. We tested the hypothesis that elevated levels of systemic immune activation among adults with HIV/TB initiating antiretroviral therapy (ART) would be associated with impaired clearance of isoniazid. METHODS: We conducted a prospective observational study of isoniazid pharmacokinetics (PK) and systemic immune activation prior to and 1 month after ART initiation. Nonlinear mixed effects analysis was performed to measure the covariate effect of immune activation on isoniazid clearance in a model that also included N-acetyltransferase-2 (NAT-2) genotype and interoccasional variability on clearance (thereby analyzing the PK data before and after ART initiation in a single model). RESULTS: We enrolled 40 patients in the PK visit prior to ART, and 24 patients returned for the second visit a median of 33 days after initiating antiretroviral therapy. The isoniazid concentration data were best described by a two-compartment model with first-order elimination. After accounting for NAT-2 genotype, increasing levels of CD38 and HLA-DR expression on CD8+ T cells (CD38+ DR+ CD8+ ) were associated with decreasing isoniazid clearance. CONCLUSION:HIV/TB patients with high levels of immune activation demonstrated impaired isoniazid clearance. Future efforts should determine the role of this relationship in clinical hepatotoxicity events.
Authors: J R Ungo; D Jones; D Ashkin; E S Hollender; D Bernstein; A P Albanese; A E Pitchenik Journal: Am J Respir Crit Care Med Date: 1998-06 Impact factor: 21.405
Authors: Galina Lyles; Oleg Ogarkov; Svetlana Zhdanova; Charles A Peloquin; Andrew Ebers; Herman Pfaeffle; Mohammad H Al-Shaer; Elena Moiseeva; Elena Zorkaltseva; Mikhail Koscheev; Eric R Houpt; Scott K Heysell Journal: Eur Respir J Date: 2018-05-24 Impact factor: 16.671
Authors: Destani J Bizune; Russell R Kempker; Michelle Kagei; Aliya Yamin; Omar Mohamed; David P Holland; Alawode Oladele; Yun F Wang; Paulina A Rebolledo; Henry M Blumberg; Susan M Ray; Marcos C Schechter Journal: AIDS Res Hum Retroviruses Date: 2018-09-11 Impact factor: 2.205
Authors: Marieke G G Sturkenboom; Anne-Grete Märtson; Elin M Svensson; Derek J Sloan; Kelly E Dooley; Simone H J van den Elsen; Paolo Denti; Charles A Peloquin; Rob E Aarnoutse; Jan-Willem C Alffenaar Journal: Clin Pharmacokinet Date: 2021-03-06 Impact factor: 6.447
Authors: Paolo Denti; Anthony J Garcia-Prats; Heather R Draper; Lubbe Wiesner; Jana Winckler; Stephanie Thee; Kelly E Dooley; Rada M Savic; Helen M McIlleron; H Simon Schaaf; Anneke C Hesseling Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191